ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.

Chen Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.